The treatment of human papillomavirus lesions of the lower genital tract.
Anogenital warts are caused by human papillomavirus types 6 and 11 infection, and are the most common clinical manifestation of lower genital tract human papillomavirus infection. They are the most frequently recognized sexually transmitted disease in the developed world, occurring at an incidence rate of 0.5-1.2% in young men and women aged 18-25 years. Many therapies for genital warts have been described, none being ideal in that all therapeutic modalities fail to clear the warts in a proportion of patients, and the recurrence of warts after successful treatment is seen with all treatments. The current knowledge base of the therapy of genital warts is flawed by a lack of good natural history data either with treatment or without treatment over longer periods of time, in that most trials report comparisons of monotherapies over a short time and there is a lack of structured trials addressing consecutive therapies over longer durations, as occurs in real-life clinical situations.
Sonnex
C
C
Department of Genitourinary Medicine, Addenbrooke's Hospital, Cambridge, UK.
Lacey
C J
CJ
D000293:Adolescent; D000328:Adult; D003218:Condylomata Acuminata / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003452:Cryosurgery / Q000379:methods; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male
D007641:Keratolytic Agents